KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EPS (Basic) (2016 - 2025)

Charles River Laboratories International has reported EPS (Basic) over the past 17 years, most recently at -$5.57 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 32.94% year-over-year to -$5.57; the TTM value through Dec 2025 reached -$2.9, down 1480.95%, while the annual FY2025 figure was -$2.91, 1555.0% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$5.57 at Charles River Laboratories International, down from $1.11 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $3.69 in Q4 2022 and troughed at -$5.57 in Q4 2025.
  • A 5-year average of $1.2 and a median of $1.76 in 2024 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): skyrocketed 49.59% in 2022 and later tumbled 214.79% in 2024.
  • Year by year, EPS (Basic) stood at $2.73 in 2021, then surged by 35.16% to $3.69 in 2022, then fell by 1.08% to $3.65 in 2023, then tumbled by 214.79% to -$4.19 in 2024, then plummeted by 32.94% to -$5.57 in 2025.
  • Business Quant data shows EPS (Basic) for CRL at -$5.57 in Q4 2025, $1.11 in Q3 2025, and $1.06 in Q2 2025.